SUBSCRIBE
SUBSCRIBE
News   Drug Development

OncoMethylome Sciences S.A. in Deal for Brain Tumor Trial

April 16, 2009 | 
1 min read
BRUSSELS, April 16 (Reuters) - OncoMethylome Sciences SA begins MGMT gene promoter methylation testing in a recently started Phase III clinical trial for the U.S.-based, Radiotherapy Oncology Group in newly diagnosed brain tumors (glioblastoma).
Clinical research Phase 3 Europe
MORE ON THIS TOPIC
Red round circle with a pause button or icon against yellow background.
Gene therapy
Liver Toxicities Force Pause on Two Dose Groups of UniQure’s Mid-Stage Fabry Study
February 9, 2026
 · 
1 min read
 · 
Tristan Manalac
A contemporary artistic collage featuring a hand holding a trophy. The concept of victory and achievement.
Gene therapy
Ultragenyx’s Gene Therapy Shows Long-Term Efficacy in Two Sanfilippo Studies
February 9, 2026
 · 
2 min read
 · 
Tristan Manalac
Graphic drawing white background
Psychedelics
AbbVie CSO Touts ‘Breakthrough Type Therapy’ Psychedelic as J&J’s Spravato Keeps Growing
February 6, 2026
 · 
2 min read
 · 
Dan Samorodnitsky
A contemporary artistic collage featuring a hand holding a trophy. The concept of victory and achievement.
Immunology and inflammation
Priovant Plots Path to Phase 3 as Brepocitinib Clears Mid-Stage Skin Disease Study
February 6, 2026
 · 
2 min read
 · 
Tristan Manalac